10 episodes

Welcome to the Defocus Media Podcast, Optometry's #1 Podcast Network! We assist in providing eyecare professionals with the latest in optometric industry news, eyewear trends and discussions of the hottest topics in the eyecare profession. Join Drs. Darryl Glover, Jennifer Lyerly and the Defocus Media network!

Defocus Media Podcast Network Defocus Media Podcast Network

    • Health & Fitness
    • 4.8 • 48 Ratings

Welcome to the Defocus Media Podcast, Optometry's #1 Podcast Network! We assist in providing eyecare professionals with the latest in optometric industry news, eyewear trends and discussions of the hottest topics in the eyecare profession. Join Drs. Darryl Glover, Jennifer Lyerly and the Defocus Media network!

    Defocus Media: Myth Busting Astigmatism Contact Lenses

    Defocus Media: Myth Busting Astigmatism Contact Lenses

    Thank you to Johnson and Johnson Vision for sponsoring this podcast episode







    “I need really thick contact lenses to keep the weight in the right place on my eye.”







    “My Contact lenses move around too much.”







    You’ve probably heard all of these comments from patients in your chair that have astigmatism and/or wear astigmatism contact lenses. We’re here to confront these misconceptions head-on and discuss strategies for having successful conversations and visual outcomes regarding astigmatism and contact lenses. Today’s expert guest is Dr. Erin Rueff, OD, PhD, FAAO and Chief of the Cornea and Contact Lens department at Marshall B. Ketchum University Eye Center. Her passion for contact lens care started early in her career when she saw the difference a lens can make. “Contact lenses can correct vision, treat ocular diseases, take someone from being disabled — walking into your room not able to drive or having difficulties performing their day to day life activities– and you can design a lens for them and they can walk out able-bodied and able to take on whatever they want in their life.” 







    Erin Rueff, OD, PhD, FAAO and Chief of the Cornea and Contact Lens department at Marshall B. Ketchum University Eye Center







    While it seems hard to believe that patients may be told that they aren’t candidates for contact lens wear due to astigmatism, the numbers show that there is a definite lag between the number of Americans that have astigmatism and those that wear astigmatism contact lenses. On average 45% of Americans have 0.75 DC or more, but toric contact lenses represent only 27% of soft contact lenses prescribed in the USA. This is despite research showing that prescribing for even low amounts of astigmatism have a significant visual benefit to patients.  “The underutilization of astigmatism contact lenses is an eye care provider problem, not a patient problem,” Dr. Rueff explains. “There’s a perception amongst eyecare providers that toric lenses are going to cost you more chair time, that they’ll be more likely to fail, and that patients won’t get as good vision.  Those things have been disproven time and again.” 







    Dr. Rueff cites a study by Dr. Stephanie Cox and Dr. David Berntsten that shows that patients with low amounts of astigmatism do achieve better objective vision in high and low contrast visual environments with toric lenses over spherical lenses. Additionally, patients achieved subjective improvements in vision when fit in astigmatism contact lenses, including improvement in eye strain complaints. 







    In reality, today’s contact lens designs provide a wide range of parameter option that serves the overwhelming majority of prescriptions with great stabilization and comfort. Studies show that ECPs significantly underestimate the percentage of their patients that are candidates for astigmatism contact lens wear. In a recent survey in the United States, ECPs were asked, “What percentage of your astigmatic patients would you say you could prescribe with just that one [reusable] product?” Responses ranged from 55% to 74% depending on the product. In actuality, the Acuvue Oasys family of lenses covers 99% of spherical and astigmatism prescriptions.







    In this episode we talk through the differences between...

    • 48 min
    Optometry Podcast: TYRVAYA™ (varenicline solution) Nasal Spray with Jeff Nau and Dr. Marian Macsai

    Optometry Podcast: TYRVAYA™ (varenicline solution) Nasal Spray with Jeff Nau and Dr. Marian Macsai

    Drs. Darryl Glover and Inna Lazar discuss TYRVAYA™ (varenicline solution) Nasal Spray with Oyster Point’s Jeff Nau, President and CEO, and Marian Macsai, Chief Medical Officer.















    06:16







    We found that oyster point with that concept of bringing transformative innovative medicines to the front of the eye. So to TYRVAYA™ was our first product that we were developing, which is obviously a little bit out of the norm, which is a nasal spray to treat an ocular surface disease. But then we also have a pipeline that is focused on bringing gene therapy to the front of the eye. So we’re actually delivering AV gene therapy to the lacrimal gland and harnessing the lacrimal gland to really do drug delivery to the ocular surface. And we think that that has the possibility to transform the way that we deliver therapeutics to the ocular surface where once we inject that patient’s lacrimal gland, the patient is set for some period of time that remains to be seen. We’re also working on some novel antimicrobial therapies in our pipeline called bacteriophages. These are really harnessing the small little viral particles to go after bacteria and we’re obviously working on a number of other things we can’t talk about just yet but we think we got the coolest pipeline in front of the eye and we got a cool company that’s really only focused on in front of the eye and many companies out there can claim that they’re in eye care, but we are truly ingrained in eye care







    12:02







    And so this particular class of receptors was identified and what’s interesting about the class of receptors is they’re made up of 5 subunits and the way that they work is once the drug or ligand binds to them, they open a pore and allow ions to flow in and that depolarizes the nerve and causes the nerve to send a signal back to the various structures that produce the tear film. And not all of these receptors will cause tearing. So very specific receptors will. And so we found that this product, this drug varenicline, which was already out on the market, was one of those drugs that will stimulate these receptors. So one of the nice things about this particular product was more than 20 million patients have taken this product orally for smoking cessation. So we had a giant safety record. Big safety database. Obviously, at much higher doses than we would deliver in the nasal cavity. And so it allowed us to move really quickly through development, but also it cleared some of those hurdles that we often run into and drug development where you don’t know what sort of safety issues you’re going to run into. And we had a well-studied product that had been in the market for a long period of time. So we felt very comfortable in delivering this to patients. So varenicline binds to that receptor, it depolarizes the nerve, a signal is then sent back up through the ganglion into the lacrimal glands and meibomian glands in the goblet cells and we get stimulation. So as long as we have healthy gland tissue healthy goblet cells, the nerve that’s opposed to them will stimulate.







    47:21







    So the drug itself is priced similar to other dry eye medications that are currently out. At the beginning, when we launch products into the marketplace as you guys know, insurance coverage takes some time. And so we put patient services into place to help patients so that they can experience the drug and help physicians so that they can get experience with the drug. So for commercially insured patients at the moment, we have programs where they can pay as little as z...

    • 54 min
    The 4 Eyed Professor: Managing Frames in the Optical

    The 4 Eyed Professor: Managing Frames in the Optical

    Lunch Date with Rachel & Kate: 2021 Wrapped

    Lunch Date with Rachel & Kate: 2021 Wrapped

    Spotify Wrapped took over our worlds this winter, so we decided we needed a wrapped of our own. We talk about what our aura was for 2021, and our top 5 things that occurred this year. And man, did we accomplish a LOT! We changed jobs, negotiated for raises, asked for you to negotiate and spoke to THOUSANDS of people about asking for what they deserve. Speaking of, it is the changing of a year, it is a great time to renegotiate your contract!

    The 2020 Podcast: Dr. Harbir Sian and Kimberly Friedman

    The 2020 Podcast: Dr. Harbir Sian and Kimberly Friedman

    The post The 2020 Podcast: Dr. Harbir Sian and Kimberly Friedman appeared first on Defocus Media.

    The 2020 Podcast: Steve Vargo

    The 2020 Podcast: Steve Vargo

    The post The 2020 Podcast: Steve Vargo appeared first on Defocus Media.

Customer Reviews

4.8 out of 5
48 Ratings

48 Ratings

EricaBushwell ,

Awesome podcast!

Dr. Lyerly & Dr. Glover, hosts of the Defocus Media Podcast Network, highlight all aspects of medicine, wellness and more in this can’t miss podcast! The hosts and expert guests offer insightful advice and information that is helpful to anyone that listens!

giannie1 ,

Great information

Awesome podcast with great information. Love listening to it on walks or in car rides.

Stay connected to optometry with this podcast!

_Leona85 ,

My favorite optometrist!

Darryl and Jen have great chemistry! You should definitely tune in! You will not be disappointed!

Top Podcasts In Health & Fitness

Scicomm Media
Scicomm Media
Jay Shetty
Dr. Mark Hyman
Aubrey Gordon & Michael Hobbes
Rob Dial and Kast Media

You Might Also Like

James Deom OD & Roya Habibi OD
Adam Cmejla
Jobson Healthcare
The Power Practice
FourEyes Optom
Dr. Dave Kading & Dr. Mile Brujic